Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ischemic Heart Disease

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 276 articles: HTML format

Single Articles

May 2022
1. SPOSITO AC
   Soluble LOX-1 levels during acute coronary syndrome: a potent and multifaceted warning sign for cardiovascular risk.
   Eur Heart J. 2022;43:1861-1863.
   PubMed    
   
   
   
2. KRALER S, Wenzl FA, Georgiopoulos G, Obeid S, et al
   Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes.
   Eur Heart J. 2022;43:1849-1860.
   PubMed     Abstract available
   
   
   
3. WANG J, Chen H, Zhang L
   Coronary artery fistula bypassed the left main coronary artery blocked by a large cardiogenic thrombus.
   Eur Heart J. 2022;43:1885.
   PubMed    
   
   
   
4. LU X, Liu Z, Cui Q, Liu F, et al
   A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study.
   Eur Heart J. 2022;43:1702-1711.
   PubMed     Abstract available
   
   
   
5. HAGEMAN SHJ, McKay AJ, Ueda P, Gunn LH, et al
   Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.
   Eur Heart J. 2022;43:1715-1727.
   PubMed     Abstract available
   
   
   
6. FRANTZ S, Hundertmark MJ, Schulz-Menger J, Bengel FM, et al
   Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.
   Eur Heart J. 2022 May 4. pii: 6578707. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2022
7. CREA F
   Inflammation, targeted proteomics, and microvascular dysfunction: the new frontiers of ischaemic heart disease.
   Eur Heart J. 2022;43:1517-1520.
   PubMed    
   
   
   
8. STEFFENS S, Nahrendorf M, Madonna R
   Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies.
   Eur Heart J. 2022;43:1533-1541.
   PubMed     Abstract available
   
   
   
9. KELSHIKER MA, Seligman H, Howard JP, Rahman H, et al
   Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis.
   Eur Heart J. 2022;43:1582-1593.
   PubMed     Abstract available
   
   
   
10. MORICI N, De Servi S, De Luca L, Crimi G, et al
    Management of acute coronary syndromes in older adults.
    Eur Heart J. 2022;43:1542-1553.
    PubMed     Abstract available
    
    
    
11. HONG S, Kim KS, Han K, Park CY, et al
    Acromegaly and cardiovascular outcomes: a cohort study.
    Eur Heart J. 2022;43:1491-1499.
    PubMed     Abstract available
    
    
    
12. FERNANDEZ ASENSIO R, Pascual Calleja I, Moris de la Tassa C, Colunga Blanco S, et al
    Pneumopericardium mimicking ST-segment elevation acute coronary syndrome.
    Eur Heart J. 2022;43:1516.
    PubMed    
    
    
    
13. SAMMONS E, Hopewell JC, Chen F, Stevens W, et al
    Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
    Eur Heart J. 2022;43:1416-1424.
    PubMed     Abstract available
    
    
    March 2022
14. BUCCIARELLI-DUCCI C, Ajmone-Marsan N, Di Carli M, Nicol E, et al
    The year in cardiovascular medicine 2021: imaging.
    Eur Heart J. 2022;43:1288-1295.
    PubMed     Abstract available
    
    
    
15. BYRNE RA, Rai H, Colleran R
    Amphilimus-eluting stents in coronary artery disease: finally, a sweet spot for patients with diabetes mellitus?
    Eur Heart J. 2022;43:1331-1333.
    PubMed    
    
    
    
16. HAN Y
    Chinese expert consensus statement on dual antiplatelet therapy in patients with coronary artery disease.
    Eur Heart J. 2022;43:1283-1285.
    PubMed    
    
    
    
17. ROMAGUERA R, Salinas P, Gomez-Lara J, Brugaletta S, et al
    Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.
    Eur Heart J. 2022;43:1320-1330.
    PubMed     Abstract available
    
    
    
18. OKA S, Endo H, Takagi K, Yamagata K, et al
    Mechanical coronary artery stenosis induced by active fixation left ventricular lead: a case of acute complication after cardiac resynchronization therapy device implantation.
    Eur Heart J. 2022;43:1271.
    PubMed    
    
    
    
19. THYGESEN K, Jaffe AS
    Revisiting the definition of perioperative myocardial infarction after coronary artery bypass grafting.
    Eur Heart J. 2022 Mar 17. pii: 6549761. doi: 10.1093.
    PubMed    
    
    
    
20. TUAL-CHALOT S, Stellos K
    Chrono-pharmacology-based antiplatelet therapy for acute myocardial infarction.
    Eur Heart J. 2022 Mar 10. pii: 6546087. doi: 10.1093.
    PubMed    
    
    
    
21. TAN S, White HD, Layland J
    Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?
    Eur Heart J. 2022;43:1008-1011.
    PubMed    
    
    
    
22. SILVAIN J, Hausenloy D, Zeitouni M
    Appropriate criteria for the definition of Type 4a MI.
    Eur Heart J. 2022;43:1013-1014.
    PubMed    
    
    
    February 2022
23. MOLEDINA SM, Kontopantelis E, Wijeysundera HC, Banerjee S, et al
    Ethnicity-dependent performance of the Global Registry of Acute Coronary Events risk score for prediction of non-ST-segment elevation myocardial infarction in-hospital mortality: nationwide cohort study.
    Eur Heart J. 2022 Feb 24. pii: 6529720. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. ZENG C, Rosenberg L, Li X, Djousse L, et al
    Sodium-containing acetaminophen and cardiovascular outcomes in individuals with and without hypertension.
    Eur Heart J. 2022 Feb 24. pii: 6535634. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. PRICE S, Katz J, Kaufmann CC, Huber K, et al
    The year in cardiovascular medicine 2021: acute cardiovascular care and ischaemic heart disease.
    Eur Heart J. 2022;43:800-806.
    PubMed    
    
    
    
26. SHRAUNER W, Lord EM, Nguyen XT, Song RJ, et al
    Frailty and cardiovascular mortality in more than 3 million US Veterans.
    Eur Heart J. 2022;43:818-826.
    PubMed     Abstract available
    
    
    
27. VAROTTO L, De Boni A, Iannucci G, Caprioglio F, et al
    Uncommon intravascular lithotripsy for the treatment of subclavian steal syndrome: a case presenting with concomitant acute coronary syndrome and transient ischaemic attack.
    Eur Heart J. 2022;43:840.
    PubMed    
    
    
    
28. LIUZZO G, Volpe M
    Percutaneous coronary intervention vs. coronary artery bypass graft for left main coronary artery disease: a never-ending debate.
    Eur Heart J. 2022 Feb 21. pii: 6533241. doi: 10.1093.
    PubMed    
    
    
    
29. LIUZZO G, Volpe M
    PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction.
    Eur Heart J. 2022;43:559-560.
    PubMed    
    
    
    
30. DE CATERINA R, Liga R, Boden WE
    Myocardial revascularization in ischaemic cardiomyopathy: routine practice vs. scientific evidence.
    Eur Heart J. 2022;43:387-390.
    PubMed    
    
    
    January 2022
31. BRAUNWALD E
    How to live to 100 before developing clinical coronary artery disease: a suggestion.
    Eur Heart J. 2022;43:249-250.
    PubMed    
    
    
    
32. SLIWICKA O, Damman P, Habets J
    Stress dynamic CT perfusion in the evaluation of acute coronary syndrome.
    Eur Heart J. 2022;43:244.
    PubMed    
    
    
    
33. CREA F
    Hot topics in ischaemic heart disease: revascularization, hibernation, type 2 infarction, and proteomics.
    Eur Heart J. 2022;43:89-92.
    PubMed    
    
    
    
34. NEWBY LK
    A new biomarker of acute coronary ischaemia: from bench to bedside?
    Eur Heart J. 2022;43:164-166.
    PubMed    
    
    
    
35. RYAN M, Morgan H, Chiribiri A, Nagel E, et al
    Myocardial viability testing: all STICHed up, or about to be REVIVED?
    Eur Heart J. 2022;43:118-126.
    PubMed     Abstract available
    
    
    
36. CUBEDO J, Padro T, Vilahur G, Crea F, et al
    Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events.
    Eur Heart J. 2022;43:153-163.
    PubMed     Abstract available
    
    
    
37. QUADRI G, Tomassini F, Cerrato E, Varbella F, et al
    Emergency treatment of a giant coronary aneurysm: percutaneous intervention with coronary and peripheral tools.
    Eur Heart J. 2022;43:168.
    PubMed    
    
    
    
38. DEMIR OM, Rahman H, van de Hoef TP, Escaned J, et al
    Invasive and non-invasive assessment of ischaemia in chronic coronary syndromes: translating pathophysiology to clinical practice.
    Eur Heart J. 2022;43:105-117.
    PubMed     Abstract available
    
    
    December 2021
39. WANG R, Serruys PW, Gao C, Hara H, et al
    Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.
    Eur Heart J. 2021;43:56-67.
    PubMed     Abstract available
    
    
    
40. NICOLAS J, Giustino G, Dangas G
    Periprocedural myocardial infarction: multiple definitions and still a quest for consensus.
    Eur Heart J. 2021 Dec 21. pii: 6471447. doi: 10.1093.
    PubMed    
    
    
    
41. LOZANO I, Vegas JM, Rondan J
    Percutaneous intervention in patients with cancer: can we offer an improvement in safety?
    Eur Heart J. 2021;42:4981.
    PubMed    
    
    
    
42. WHITE HD, Schwartz GG, Szarek M, Bhatt DL, et al
    Alirocumab after acute coronary syndrome in patients with a history of heart failure.
    Eur Heart J. 2021 Dec 18. pii: 6469637. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. GALLI M, Benenati S, Franchi F, Rollini F, et al
    Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Eur Heart J. 2021 Dec 16. pii: 6464193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. CREA F
    Percutaneous coronary interventions: more complex than fixing stenoses.
    Eur Heart J. 2021;42:4607-4611.
    PubMed    
    
    
    
45. WHITE HD
    Cardiac death should be the primary endpoint for revascularization trials and meta-analyses.
    Eur Heart J. 2021;42:4697-4698.
    PubMed    
    
    
    
46. AL-LAMEE R, Mintz GS
    What are the PROSPECTs and clinical implications of vulnerable plaque?
    Eur Heart J. 2021;42:4680-4682.
    PubMed    
    
    
    
47. KEDHI E, Berta B, Roleder T, Hermanides RS, et al
    Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial.
    Eur Heart J. 2021;42:4671-4679.
    PubMed     Abstract available
    
    
    November 2021
48. EGGERS KM, James SK, Lindahl B
    Myocardial infarction after elective percutaneous coronary intervention-which cardiac troponin cut-off to use?
    Eur Heart J. 2021 Nov 24. pii: 6438090. doi: 10.1093.
    PubMed    
    
    
    
49. BOR WL, Ten Berg JM
    Known or new atrial fibrillation in patients with acute coronary syndrome: what's the difference?
    Eur Heart J. 2021;42:4562-4564.
    PubMed    
    
    
    
50. DE SILVA R, Cheng K
    Microvascular angina: quo tendimus?
    Eur Heart J. 2021;42:4601-4604.
    PubMed    
    
    
    
51. SHIMOKAWA H, Suda A, Takahashi J, Berry C, et al
    Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group.
    Eur Heart J. 2021;42:4592-4600.
    PubMed     Abstract available
    
    
    
52. PITT B, Ferreira JP, Zannad F
    Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
    Eur Heart J. 2021 Nov 12. pii: 6425576. doi: 10.1093.
    PubMed    
    
    
    
53. CHIKWE J, Alfieri OR
    The optimal strategy for multivessel coronary revascularization.
    Eur Heart J. 2021 Nov 11. pii: 6425621. doi: 10.1093.
    PubMed    
    
    
    
54. WINTHER S, Schmidt SE, Knuuti J, Bottcher M, et al
    Selecting the right cohorts and endpoints for the validation of pre-test probability models for obstructive coronary artery disease.
    Eur Heart J. 2021;42:4402-4403.
    PubMed    
    
    
    
55. DERIMAY F, Finet G, Rioufol G
    Coronary artery stenosis prediction does not mean coronary artery stenosis obstruction.
    Eur Heart J. 2021;42:4401.
    PubMed    
    
    
    
56. EGIDY ASSENZA G, Dimopoulos K, Budts W, Donti A, et al
    Management of acute cardiovascular complications in pregnancy.
    Eur Heart J. 2021;42:4224-4240.
    PubMed     Abstract available
    
    
    October 2021
57. BIAN L, Fang Z, Qian H, Wu Z, et al
    Dumbbell on the heart: two giant left coronary artery aneurysms in an adolescent.
    Eur Heart J. 2021;42:4195.
    PubMed    
    
    
    
58. AHN JM, Zimmermann FM, Arora S, Solberg OG, et al
    Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation.
    Eur Heart J. 2021 Oct 19. pii: 6401958. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. TSUDA K, Kanzaki Y, Hoshiga M
    Early cardiac magnetic resonance leads to diagnose the etiology of myocardial infarction with non-obstructive coronary arteries.
    Eur Heart J. 2021 Oct 18. pii: 6400298. doi: 10.1093.
    PubMed    
    
    
    
60. WADSTROM BN, Wulff AB, Pedersen KM, Jensen GB, et al
    Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study.
    Eur Heart J. 2021 Oct 18. pii: 6399975. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. LECHNER I, Reindl M, Tiller C, Holzknecht M, et al
    Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study.
    Eur Heart J. 2021 Oct 11. pii: 6386704. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. BANNING AP, Serruys P, De Maria GL, Ryan N, et al
    Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.
    Eur Heart J. 2021 Oct 7. pii: 6383065. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. CREA F
    The challenge of risk stratification in suspected angina, in myocardial infarction without risk factors, and in frail patients.
    Eur Heart J. 2021;42:3807-3811.
    PubMed    
    
    
    
64. CURZEN N, Nicholas Z, Stuart B, Wilding S, et al
    Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial.
    Eur Heart J. 2021;42:3844-3852.
    PubMed     Abstract available
    
    
    September 2021
65. HAN Y
    Long-term outcomes of new-generation coronary stents in China.
    Eur Heart J. 2021 Sep 18. pii: 6372216. doi: 10.1093.
    PubMed    
    
    
    
66. GRINES CL, Mehta S
    ST-segment elevation myocardial infarction management: great strides but still room for improvement.
    Eur Heart J. 2021 Sep 16. pii: 6371299. doi: 10.1093.
    PubMed    
    
    
    
67. SINHA A, Rahman H, Webb A, Shah AM, et al
    Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.
    Eur Heart J. 2021 Sep 16. pii: 6371296. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. PETERS SAE, Kluin J
    Why do women do worse after coronary artery bypass grafting?
    Eur Heart J. 2021 Sep 15. pii: 6370651. doi: 10.1093.
    PubMed    
    
    
    
69. JAFFER FA, Mehilli J, Escaned J
    Left main coronary disease at the bifurcation: should the pendulum swing back towards the provisional stenting approach?
    Eur Heart J. 2021 Sep 13. pii: 6368942. doi: 10.1093.
    PubMed    
    
    
    
70. LOPEZ-SENDON JL, Cyr DD, Mark DB, Bangalore S, et al
    Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial.
    Eur Heart J. 2021 Sep 13. pii: 6368943. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. PETERSEN JK, Haider Butt J, Yafasova A, Torp-Pedersen C, et al
    Incidence of ischaemic stroke and mortality in patients with acute coronary syndrome and first-time detected atrial fibrillation: a nationwide study.
    Eur Heart J. 2021 Sep 3. pii: 6363625. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. MESSIKA-ZEITOUN D, Hibbert B, Chan V
    'Primary' percutaneous mitral valve repair in patients with acute myocardial infarction: is it ready for primetime?
    Eur Heart J. 2021 Sep 2. pii: 6362540. doi: 10.1093.
    PubMed    
    
    
    August 2021
73. HABERMAN D, Estevez-Loureiro R, Benito-Gonzalez T, Denti P, et al
    Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction.
    Eur Heart J. 2021 Aug 31. pii: 6360026. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. CREA F
    Pulmonary embolism, COVID, and bleeding risk in acute coronary syndromes: a Focus Issue on thrombosis and antithrombotic treatment.
    Eur Heart J. 2021;42:3109-3113.
    PubMed    
    
    
    
75. YANG Q, Sun D, Pei C, Zeng Y, et al
    LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project.
    Eur Heart J. 2021;42:3175-3186.
    PubMed     Abstract available
    
    
    
76. CERRATO E, Giacobbe F, Quadri G, Macaya F, et al
    Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry.
    Eur Heart J. 2021;42:3161-3171.
    PubMed     Abstract available
    
    
    
77. WERESKI R, Kimenai DM, Bularga A, Taggart C, et al
    Risk factors for type 1 and type 2 myocardial infarction.
    Eur Heart J. 2021 Aug 25. pii: 6357312. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. LUSEBRINK E, Massberg S, Orban M
    The lack of evidence-based therapeutic strategies for left ventricular unloading during venoarterial extracorporeal membrane oxygenation therapy calls for randomized trials.
    Eur Heart J. 2021;42:3105-3106.
    PubMed    
    
    
    
79. KLOECKNER M, Guihaire J, Hascoet S
    Congestive pulmonary oedema during venoarterial extracorporeal membrane oxygenation support: a plea for balloon atrial septostomy.
    Eur Heart J. 2021;42:3103-3104.
    PubMed    
    
    
    
80. DAVIERWALA PM, Gao C, Thuijs DJFM, Wang R, et al
    Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.
    Eur Heart J. 2021 Aug 18. pii: 6354120. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. BOSCH J, Lonn EM, Jung H, Zhu J, et al
    Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.
    Eur Heart J. 2021;42:2995-3007.
    PubMed     Abstract available
    
    
    
82. LEONE AM, Liuzzo G
    No blossom for fractional flow reserve in FLOWER-MI.
    Eur Heart J. 2021;42:2971-2972.
    PubMed    
    
    
    
83. YANG H, Chang S, Qian J, Ge J, et al
    A gigantic coronary pseudoaneurysm in a 60-year-old man.
    Eur Heart J. 2021;42:3027.
    PubMed    
    
    
    
84. ZEYMER U, Ludman P, Danchin N, Kala P, et al
    Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology.
    Eur Heart J. 2021 Aug 14. pii: 6352178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. WANG N, Sun Y, Zhang H, Wang B, et al
    Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.
    Eur Heart J. 2021 Aug 10. pii: 6347324. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. DE CATERINA R, Brown DL
    Interpreting myocardial infarction analyses in ISCHEMIA: separating facts from fallacy.
    Eur Heart J. 2021 Aug 5. pii: 6342393. doi: 10.1093.
    PubMed    
    
    
    
87. GAUDINO M, Di Franco A, Alexander JH, Bakaeen F, et al
    Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data.
    Eur Heart J. 2021 Aug 2. pii: 6333765. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
88. KOSYAKOVSKY LB, Austin PC, Ross HJ, Wang X, et al
    Early invasive coronary angiography and acute ischaemic heart failure outcomes.
    Eur Heart J. 2021 Jul 30. pii: 6331345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. GOROG DA, Navarese EP, Andreotti F
    Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
    Eur Heart J. 2021 Jul 29. pii: 6330652. doi: 10.1093.
    PubMed    
    
    
    
90. CREA F
    Addressing Residual Risk in Ischaemic Heart Disease with Anti-Inflammatory Drugs: Between Scylla and Charybdis.
    Eur Heart J. 2021;42:2715-2719.
    PubMed    
    
    
    
91. WACKER J, Malaspinas I, Vallee JP, Beghetti M, et al
    Regression of coronary arteries aneurysms 6 months after multisystem inflammatory syndrome in children (MIS-C).
    Eur Heart J. 2021;42:2803.
    PubMed    
    
    
    
92. ANSELMO A, Frank D, Papa L, Viviani Anselmi C, et al
    Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release.
    Eur Heart J. 2021;42:2780-2792.
    PubMed     Abstract available
    
    
    
93. STRANDBERG TE, Kovanen PT
    Coronary artery disease: 'gout' in the artery?
    Eur Heart J. 2021;42:2761-2764.
    PubMed    
    
    
    
94. PRADHAN AD
    Time to commence or time out for colchicine in secondary prevention of cardiovascular disease?
    Eur Heart J. 2021;42:2776-2779.
    PubMed    
    
    
    
95. ANGELINI F, Bocchino PP, Imazio M
    Colchicine and coronary artery disease: a virtuous adoption.
    Eur Heart J. 2021;42:2796-2797.
    PubMed    
    
    
    
96. BOUABDALLAOUI N, Blondeau L, Tardif JC
    Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease.
    Eur Heart J. 2021;42:2800-2801.
    PubMed    
    
    
    
97. COLLISON D, Didagelos M, Aetesam-Ur-Rahman M, Copt S, et al
    Post-stenting fractional flow reserve vs coronary angiography for optimisation of percutaneous coronary intervention: TARGET-FFR trial.
    Eur Heart J. 2021 Jul 19. pii: 6323924. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. MADHAVAN MV, Howard JP, Naqvi A, Ben-Yehuda O, et al
    Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.
    Eur Heart J. 2021;42:2643-2654.
    PubMed     Abstract available
    
    
    
99. ABDELWAHED YS, Schatz AS, Landmesser U, Skurk C, et al
    'Small bifurcation?' CT myocardial mass volume measurements change therapeutic strategy in coronary artery disease.
    Eur Heart J. 2021;42:2713-2714.
    PubMed    
    
    
    
100. CREA F
     The growing complexity of the number one killer: ischaemic heart disease.
     Eur Heart J. 2021;42:2513-2517.
     PubMed    
     
     
     
101. OIKONOMOU EK, Van Dijk D, Parise H, Suchard MA, et al
     A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST).
     Eur Heart J. 2021;42:2536-2548.
     PubMed     Abstract available
     
     
     
102. COLLET JP, Thiele H
     Lesson learnt from the new 2020 ESC guidelines on non-ST-segment elevation acute coronary syndrome: when clinical judgement precedes and overpasses weak recommendations. 2020 non-ST-segment elevation acute coronary syndrome guidelines on pre-treatment
     Eur Heart J. 2021;42:2607-2608.
     PubMed    
     
     
     
103. COLLET JP, Thiele H
     Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?
     Eur Heart J. 2021;42:2611-2612.
     PubMed    
     
     
     
104. SANNA GD
     Lesson learnt from the new 2020 ESC guidelines on NSTE-ACS: when clinical judgement precedes and overpasses weak recommendations.
     Eur Heart J. 2021;42:2605-2606.
     PubMed    
     
     
     
105. KOW CS, Zaihan AF, Hasan SS
     Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?
     Eur Heart J. 2021;42:2609-2610.
     PubMed    
     
     
     
106. SHENOY S, Singh A, Acharya T
     Incidental isolated septal infarct in a young patient with colon cancer.
     Eur Heart J. 2021;42:2613.
     PubMed    
     
     
     
107. 
     SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.
     Eur Heart J. 2021;42:2455-2467.
     PubMed     Abstract available
     
     
     
108. OZKAN J
     Patient Perspective: Maria George founder of INOCA International.
     Eur Heart J. 2021;42:2408-2410.
     PubMed    
     
     
     June 2021
109. VOLPE M, Patrono C
     The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk.
     Eur Heart J. 2021;42:2329-2330.
     PubMed    
     
     
     
110. CREA F
     The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy.
     Eur Heart J. 2021;42:2317-2320.
     PubMed    
     
     
     
111. HUBER K
     Scores for outcome prediction in patients admitted with cardiogenic shock.
     Eur Heart J. 2021;42:2353-2355.
     PubMed    
     
     
     
112. LUSEBRINK E, Massberg S, Orban M
     The multiple options of left atrial and ventricular venting during veno-arterial extra-corporeal membrane oxygenation: practical considerations.
     Eur Heart J. 2021;42:2399-2400.
     PubMed    
     
     
     
113. POZZI M, Grinberg D, Rioufol G
     Percutaneous left ventricular unloading in veno-arterial extracorporeal membrane oxygenation.
     Eur Heart J. 2021;42:2397-2398.
     PubMed    
     
     
     
114. VOLPE M, Patrono C
     Vulnerable non-culprit coronary plaques: are they worth treating?
     Eur Heart J. 2021;42:2233-2234.
     PubMed    
     
     
     
115. COLLET JP, Thiele H
     Major bleeding and the ADP-binding enzyme creatine kinase in non-ST-segment elevation acute coronary syndromes.
     Eur Heart J. 2021;42:2313-2314.
     PubMed    
     
     
     
116. BREWSTER LM
     Because of its association with major bleeding the ADP-binding enzyme creatine kinase should be estimated in studies of patients treated for non-ST-segment elevation acute coronary syndromes (NSTE-ACS).
     Eur Heart J. 2021;42:2311-2312.
     PubMed    
     
     
     May 2021
117. BULLUCK H, Paradies V, Barbato E, Baumbach A, et al
     Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardio
     Eur Heart J. 2021 May 31. pii: 6290281. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. VARBO A, Nordestgaard BG
     Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction.
     Eur Heart J. 2021 May 23. pii: 6282433. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. VAN DER STOUWE JG, Boeddinghaus J, Mueller C
     Long-term beta-blocker treatment in stable patients after myocardial infarction: a potential impact due to changes in the diagnosis of myocardial infarction?
     Eur Heart J. 2021 May 23. pii: 6282428. doi: 10.1093.
     PubMed    
     
     
     
120. HOLT A, Blanche P, McGettigan P, Lamberts M, et al
     Temporal changes in myocardial infarction diagnostic criteria do not account for the lack of long-term beta-blocker effect on cardiovascular prognosis.
     Eur Heart J. 2021 May 23. pii: 6282429. doi: 10.1093.
     PubMed    
     
     
     
121. 
     Corrigendum to: Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomised trials.
     Eur Heart J. 2021 May 23. pii: 6282430. doi: 10.1093.
     PubMed    
     
     
     
122. VOLZ S, Redfors B, Angeras O, Ioanes D, et al
     Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
     Eur Heart J. 2021 May 23. pii: 6282431. doi: 10.1093.
     PubMed     Abstract available
     
     
     
123. NAVARESE EP, Lansky AJ, Kereiakes DJ, Kubica J, et al
     Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.
     Eur Heart J. 2021 May 18. pii: 6276780. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2021
124. JANSEN TPJ, Damman P, Nijveldt R
     Diagnostic necessity of cardiac MRI in myocardial infarction with no obstructive coronary arteries: an illustration.
     Eur Heart J. 2021 Apr 14. pii: 6225950. doi: 10.1093.
     PubMed    
     
     
     
125. CREA F
     Guidelines on myocardial infarction, novel therapeutic targets in post-infarction remodelling, and a debate on the ISCHEMIA trial.
     Eur Heart J. 2021;42:1277-1280.
     PubMed    
     
     
     
126. BODEN WE, Stone PH
     To stent or not to stent? Treating angina after ISCHEMIA-why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial.
     Eur Heart J. 2021;42:1394-1400.
     PubMed    
     
     
     
127. GERSH BJ, Boden WE, Bhatt DL, Stone PH, et al
     To stent or not to stent? Treating angina after ISCHEMIA-introduction.
     Eur Heart J. 2021;42:1387-1388.
     PubMed    
     
     
     
128. GERSH BJ, Bhatt DL
     To stent or not to stent? Treating angina after ISCHEMIA-the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease.
     Eur Heart J. 2021;42:1389-1393.
     PubMed    
     
     
     
129. GAUDINO M, Di Franco A, Bhatt DL, Alexander JH, et al
     The association between coronary graft patency and clinical status in patients with coronary artery disease.
     Eur Heart J. 2021;42:1433-1441.
     PubMed     Abstract available
     
     
     
130. RADICO F, Zimarino M, De Caterina R
     Is coronary flow velocity reserve just a marker of a higher atherosclerotic burden?
     Eur Heart J. 2021;42:1444-1445.
     PubMed    
     
     
     
131. SCHRODER J, Prescott E
     Coronary flow velocity reserve adds prognostic information beyond presence or absence of non-obstructive coronary atherosclerosis.
     Eur Heart J. 2021;42:1442-1443.
     PubMed    
     
     
     
132. SECHTEM U, Ong P
     Coronary stenoses in patients suspected to have obstructive coronary artery disease: the exemption rather than the rule!
     Eur Heart J. 2021;42:1412-1414.
     PubMed    
     
     
     
133. WINTHER S, Schmidt SE, Rasmussen LD, Juarez Orozco LE, et al
     Validation of the European Society of Cardiology pre-test probability model for obstructive coronary artery disease.
     Eur Heart J. 2021;42:1401-1411.
     PubMed     Abstract available
     
     
     
134. COLLET JP, Thiele H, Barbato E, Barthelemy O, et al
     2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
     Eur Heart J. 2021;42:1289-1367.
     PubMed    
     
     
     
135. BARBATO E, Mehilli J, Sibbing D, Siontis GCM, et al
     Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients present
     Eur Heart J. 2021;42:1368-1378.
     PubMed    
     
     
     
136. BARTHELEMY O, Jobs A, Meliga E, Mueller C, et al
     Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
     Eur Heart J. 2021;42:1379-1386.
     PubMed    
     
     
     
137. DING D, Huang J, Westra J, Cohen DJ, et al
     Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions.
     Eur Heart J. 2021 Apr 5. pii: 6211340. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2021
138. FRIGERIO M
     Fausto Rovelli (1918-2021): the father of Italian cardiology, pioneer of early reperfusion therapy for acute myocardial infarction, and unforgettable master for his hospital colleagues.
     Eur Heart J. 2021 Mar 29. pii: 6199127. doi: 10.1093.
     PubMed    
     
     
     
139. FIOLET ATL, Opstal TSJ, Mosterd A, Eikelboom JW, et al
     Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.
     Eur Heart J. 2021 Mar 26. pii: 6188997. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. ZHANG H, Xiao Z, Yang P, Hu J, et al
     Ruptured coronary artery aneurysm mimicking as a giant mediastinal mass.
     Eur Heart J. 2021;42:1183.
     PubMed    
     
     
     
141. KWOK CS, Wong CW, Kontopantelis E, Barac A, et al
     Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA.
     Eur Heart J. 2021;42:1019-1034.
     PubMed     Abstract available
     
     
     
142. MARENZI G, Cosentino N, Cardinale D
     Ischaemic and bleeding risk in cancer patients undergoing PCI: another brick in the wall.
     Eur Heart J. 2021;42:1035-1037.
     PubMed    
     
     
     
143. ERDMANN J, van der Laan SW
     Unfolding and disentangling coronary vascular disease through genome-wide association studies.
     Eur Heart J. 2021;42:934-937.
     PubMed    
     
     
     
144. VAN DIEPEN S, Armstrong PW
     Learning whether to subtract beta-blockers: it's about time.
     Eur Heart J. 2021;42:915-918.
     PubMed     Abstract available
     
     
     
145. IBANEZ B, Roque D, Price S
     The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care.
     Eur Heart J. 2021;42:884-895.
     PubMed    
     
     
     
146. WANG X, Yan C
     Progression of artery aneurysm after transcatheter closure of coronary artery fistula.
     Eur Heart J. 2021;42:918.
     PubMed    
     
     
     February 2021
147. CEGLAREK U, Schellong P, Rosolowski M, Scholz M, et al
     The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction.
     Eur Heart J. 2021 Feb 27. pii: 6153946. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. REFFO E, Stritoni V, Di Salvo G
     Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction.
     Eur Heart J. 2021 Feb 20. pii: 6145783. doi: 10.1093.
     PubMed    
     
     
     
149. BOUABDALLAOUI N, Tardif JC
     Initiation of low-dose colchicine early after myocardial infarction.
     Eur Heart J. 2021 Feb 4. pii: 6127594. doi: 10.1093.
     PubMed    
     
     
     
150. HARTIALA JA, Han Y, Jia Q, Hilser JR, et al
     Genome-wide analysis identifies novel susceptibility loci for myocardial infarction.
     Eur Heart J. 2021 Feb 3. pii: 6126843. doi: 10.1093/eurheartj/ehaa1040.
     PubMed     Abstract available
     
     
     
151. BERGONTI M
     Emergency Room visits in the COVID-19 pandemic.
     Eur Heart J. 2021;42:369-370.
     PubMed    
     
     
     January 2021
152. XING Y, Dai N, Li H
     Is abnormal function with troponin T elevation definitely myocardial infarction?
     Eur Heart J. 2021 Jan 30. pii: 6124030. doi: 10.1093.
     PubMed    
     
     
     
153. VAN DER SANGEN NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, et al
     Patient-tailored antithrombotic therapy following percutaneous coronary intervention.
     Eur Heart J. 2021 Jan 29. pii: 6122862. doi: 10.1093/eurheartj/ehaa1097.
     PubMed     Abstract available
     
     
     
154. LUNARDI M, Onuma Y, Serruys PW
     Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?
     Eur Heart J. 2021 Jan 27. pii: 6121205. doi: 10.1093.
     PubMed    
     
     
     
155. VRACHATIS DA, Giannopoulos GV, Deftereos SG
     Colchicine administered early in acute myocardial infarction: ready, set ... go?
     Eur Heart J. 2021 Jan 22. pii: 6106966. doi: 10.1093.
     PubMed    
     
     
     
156. 
     Corrigendum to: Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era.
     Eur Heart J. 2021;42:322.
     PubMed    
     
     
     
157. JOBS A, Collet JP, Thiele H
     Optimal timing of invasive angiography in non-ST-segment elevation acute coronary syndromes-do we need more data?
     Eur Heart J. 2021;42:353-354.
     PubMed    
     
     
     
158. KITE TA, Gershlick AH
     High-risk NSTE-ACS: high time for robust data.
     Eur Heart J. 2021;42:352.
     PubMed    
     
     
     
159. SCHRODER J, Michelsen MM, Mygind ND, Suhrs HE, et al
     Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study.
     Eur Heart J. 2021;42:228-239.
     PubMed     Abstract available
     
     
     
160. RAY KK
     Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care.
     Eur Heart J. 2021;42:253-256.
     PubMed    
     
     
     
161. DAVIES A, Fox K, Galassi AR, Banai S, et al
     Management of refractory angina: an update.
     Eur Heart J. 2021;42:269-283.
     PubMed     Abstract available
     
     
     
162. SICARI R
     The curious incident of CFVR in clinical practice.
     Eur Heart J. 2021;42:240-242.
     PubMed    
     
     
     
163. PLAT J, Strandberg TE, Gylling H
     Intestinal cholesterol and phytosterol absorption and the risk of coronary artery disease.
     Eur Heart J. 2021;42:281-282.
     PubMed    
     
     
     
164. HELGADOTTIR A, Thorleifsson G, Stefansson K
     Increased absorption of phytosterols is the simplest and most plausible explanation for coronary artery disease risk not accounted for by non-HDL cholesterol in high cholesterol absorbers.
     Eur Heart J. 2021;42:283-284.
     PubMed    
     
     
     
165. ABDELWAHED YS, Wurster TH, Landmesser U, Leistner DM, et al
     Culprit mistaken: development of a traumatic coronary aneurysm after mismatched culprit lesion-PCI for plaque rupture.
     Eur Heart J. 2021;42:287.
     PubMed    
     
     
     
166. KOLBE M, Lopez-Ayala P, Mueller C
     Women who experience a myocardial infarction at a young age.
     Eur Heart J. 2021 Jan 19. pii: 6104220. doi: 10.1093.
     PubMed    
     
     
     
167. CHATTOPADHYAY S, John J
     Women experiencing myocardial infarction at a young age have worse outcomes compared with men: only for non-cardiovascular deaths and when treated inadequately?
     Eur Heart J. 2021 Jan 17. pii: 6103003. doi: 10.1093.
     PubMed    
     
     
     
168. HOLT A, Blanche P, Zareini B, Rajan D, et al
     Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
     Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
     PubMed     Abstract available
     
     
     
169. MONACO C, Cole J
     Does a myocardial infarction boost your (B cell) memory?
     Eur Heart J. 2021 Jan 4. pii: 6061967. doi: 10.1093/eurheartj/ehaa1059.
     PubMed    
     
     
     
170. LIN S, Chen S, Zhe Z
     Model assessment: new measures should be known and traditional measures should be accurately interpreted.
     Eur Heart J. 2021;42:134-135.
     PubMed    
     
     
     
171. AMINORROAYA A, Tajdini M, Masoudkabir F
     Time for clinicians to revisit their perspectives on C-statistic.
     Eur Heart J. 2021;42:132-133.
     PubMed    
     
     
     
172. LAWLER PR, Bhatt DL, Godoy LC, Luscher TF, et al
     Targeting cardiovascular inflammation: next steps in clinical translation.
     Eur Heart J. 2021;42:113-131.
     PubMed     Abstract available
     
     
     December 2020
173. CAO D, Chandiramani R, Chiarito M, Claessen BE, et al
     Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey.
     Eur Heart J. 2020 Dec 26. pii: 6050475. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. SCHUBERT J, Lindahl B, Melhus H, Renlund H, et al
     Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study.
     Eur Heart J. 2020 Dec 24. pii: 6047259. doi: 10.1093/eurheartj/ehaa1011.
     PubMed     Abstract available
     
     
     
175. FIOLET ATL, Nidorf SM, Cornel JH
     Colchicine for secondary prevention in coronary disease.
     Eur Heart J. 2020 Dec 21. pii: 6042608. doi: 10.1093.
     PubMed    
     
     
     
176. KYAW T, Loveland P, Kanellakis P, Cao A, et al
     Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms.
     Eur Heart J. 2020 Dec 18. pii: 6041767. doi: 10.1093.
     PubMed     Abstract available
     
     
     
177. KOTANIDIS CP, Antoniades C
     Selfies in cardiovascular medicine: welcome to a new era of medical diagnostics.
     Eur Heart J. 2020;41:4412-4414.
     PubMed    
     
     
     
178. ROY R, Koch WJ
     Adding another GRK to the fire of heart failure.
     Eur Heart J. 2020 Dec 7. pii: 6025474. doi: 10.1093.
     PubMed    
     
     
     
179. LI L, Fu W, Gong X, Chen Z, et al
     The role of G protein-coupled receptor kinase 4 in cardiomyocyte injury after myocardial infarction.
     Eur Heart J. 2020 Dec 6. pii: 6024960. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2020
180. SILVAIN J, Zeitouni M, Paradies V, Zheng HL, et al
     Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data.
     Eur Heart J. 2020 Nov 30. pii: 6012927. doi: 10.1093.
     PubMed     Abstract available
     
     
     
181. ORWAT S, Diller GP
     Congenital heart defects as an intrinsic additional risk factor for the occurrence and outcome of myocardial infarction.
     Eur Heart J. 2020 Nov 22. pii: 5998317. doi: 10.1093.
     PubMed    
     
     
     
182. FEDCHENKO M, Mandalenakis Z, Giang KW, Rosengren A, et al
     Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study.
     Eur Heart J. 2020 Nov 21. pii: 5997447. doi: 10.1093.
     PubMed     Abstract available
     
     
     
183. MUNZEL T, Hahad O, Daiber A
     The dark side of nocturnal light pollution. Outdoor light at night increases risk of coronary heart disease.
     Eur Heart J. 2020 Nov 21. pii: 5998262. doi: 10.1093.
     PubMed    
     
     
     
184. BOHM M, Mahfoud F
     J-curve revisited.
     Eur Heart J. 2020;41:4283.
     PubMed    
     
     
     
185. LIEW CH, McEvoy JW
     The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.
     Eur Heart J. 2020;41:4284-4285.
     PubMed    
     
     
     
186. SUN S, Cao W, Ge Y, Ran J, et al
     Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study.
     Eur Heart J. 2020 Nov 17. pii: 5986682. doi: 10.1093.
     PubMed     Abstract available
     
     
     
187. ARSENOS P, Antoniou CK, Gatzoulis KA
     Risk stratification refinement and implantable cardioverter defibrillator protection for the coronary artery disease patients with a preserved left ventricular systolic function with a two-step programmed ventricular stimulation-inclusive approach.
     Eur Heart J. 2020 Nov 16. pii: 5983737. doi: 10.1093.
     PubMed    
     
     
     
188. NEUVILLERS L, Veugeois A, Didier J, Paul JF, et al
     Myocardial infarction with non-obstructive coronary artery revealing a heart tumour.
     Eur Heart J. 2020 Nov 13. pii: 5981589. doi: 10.1093.
     PubMed    
     
     
     
189. COLLET JP, Thiele H
     Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation.
     Eur Heart J. 2020 Nov 13. pii: 5981490. doi: 10.1093.
     PubMed    
     
     
     
190. NICHOLLS M
     Australia and colchicine for coronary heart disease.
     Eur Heart J. 2020 Nov 10. pii: 5961660. doi: 10.1093.
     PubMed    
     
     
     
191. VERDECCHIA P, Angeli F, Cavallini C
     Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation.
     Eur Heart J. 2020 Nov 9. pii: 5964168. doi: 10.1093.
     PubMed    
     
     
     
192. LUSCHER TF
     The sooner, the better: anti-inflammation in acute myocardial infarction.
     Eur Heart J. 2020;41:4100-4102.
     PubMed    
     
     
     
193. VRACHATIS DA, Deftereos S, Stefanini GG
     STEMI in COVID-19 patients: thrombolysis-first approach could yield more risk than benefit.
     Eur Heart J. 2020;41:4141-4142.
     PubMed    
     
     
     
194. ZHANG L, Fan Y, Lu Z
     Compromised STEMI reperfusion strategy in the era of COVID-19 pandemic: pros and cons.
     Eur Heart J. 2020;41:4143.
     PubMed    
     
     
     
195. CANNON CP
     Chronic kidney disease: a high-risk group that deserves intensive lipid lowering.
     Eur Heart J. 2020;41:4124-4126.
     PubMed    
     
     
     
196. MELE M, Casavecchia G, Ieva R, Brunetti ND, et al
     Diagnosis of acute myocardial infarction in the time of the COVID-19 pandemic.
     Eur Heart J. 2020 Nov 4. pii: 5956256. doi: 10.1093.
     PubMed    
     
     
     October 2020
197. BATKAI S, Genschel C, Viereck J, Rump S, et al
     CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
     Eur Heart J. 2020 Oct 22. pii: 5934677. doi: 10.1093.
     PubMed     Abstract available
     
     
     
198. LANDMESSER U, Luscher TF
     Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3.
     Eur Heart J. 2020;41:3946-3948.
     PubMed    
     
     
     
199. TOKGOZOGLU L, Catapano AL
     Can EPA evaporate plaques?
     Eur Heart J. 2020;41:3933-3935.
     PubMed    
     
     
     
200. BALLANTYNE CM, Virani SS
     Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?
     Eur Heart J. 2020;41:3910-3912.
     PubMed    
     
     
     
201. CHANDRASEKAR B, Alanbaei M
     Intracoronary imaging identifies plaque rupture underlying left main thrombosis in acute myocardial infarction without angiographically evident atherosclerosis.
     Eur Heart J. 2020 Oct 14. pii: 5922862. doi: 10.1093.
     PubMed    
     
     
     
202. BONNET M, Champagnac A, Lantelme P, Harbaoui B, et al
     Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
     Eur Heart J. 2020;41:3863-3864.
     PubMed    
     
     
     
203. TWEET MS
     Sex differences among young individuals with myocardial infarction.
     Eur Heart J. 2020 Oct 13. pii: 5921646. doi: 10.1093.
     PubMed    
     
     
     
204. DEFILIPPIS EM, Collins BL, Singh A, Biery DW, et al
     Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry.
     Eur Heart J. 2020 Oct 13. pii: 5921645. doi: 10.1093.
     PubMed     Abstract available
     
     
     
205. LIUZZO G, Patrono C
     Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial.
     Eur Heart J. 2020 Oct 7. pii: 5918829. doi: 10.1093.
     PubMed    
     
     
     
206. BOLLI R
     Cell therapy for acute myocardial infarction: Requiescat in Pace.
     Eur Heart J. 2020;41:3711-3714.
     PubMed    
     
     
     
207. LANSKY A, Grubman D, Scheller B
     Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis.
     Eur Heart J. 2020;41:3729-3731.
     PubMed    
     
     
     
208. STOREY RF
     The long journey of individualizing antiplatelet therapy after acute coronary syndromes.
     Eur Heart J. 2020;41:3546-3548.
     PubMed    
     
     
     
209. LIUZZO G, Pedicino D, Vinci R, Crea F, et al
     CD8 lymphocytes and plaque erosion: a new piece in the jigsaw.
     Eur Heart J. 2020;41:3561-3563.
     PubMed    
     
     
     
210. BABER U, Dangas G, Angiolillo DJ, Cohen DJ, et al
     Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
     Eur Heart J. 2020;41:3533-3545.
     PubMed     Abstract available
     
     
     September 2020
211. PARODI G, Sanna GD, Saba PS
     Understanding the complex interplay between coronary artery disease and Takotsubo syndrome: not all swans are white.
     Eur Heart J. 2020;41:3268-3270.
     PubMed    
     
     
     
212. WALTERSCHEID B, Nguyen J, Tarbox M, Eshak N, et al
     Clopidogrel-induced sweet syndrome: severe dermatological complication after percutaneous coronary intervention.
     Eur Heart J. 2020 Sep 4. pii: 5901663. doi: 10.1093.
     PubMed    
     
     
     
213. LIBERALE L, Gorog DA
     Low-grade endotoxaemia and platelets: a deadly aggregation.
     Eur Heart J. 2020;41:3166-3168.
     PubMed    
     
     
     
214. SCHUPKE S, Kastrati A
     Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor.
     Eur Heart J. 2020;41:3153-3155.
     PubMed    
     
     
     August 2020
215. VRANCKX P, Valgimigli M, Eckardt L, Lewalter T, et al
     Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
     Eur Heart J. 2020 Aug 29. pii: 5898835. doi: 10.1093.
     PubMed     Abstract available
     
     
     
216. TUNON J, Steg PG, Bhatt DL, Bittner VA, et al
     Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
     Eur Heart J. 2020 Aug 21. pii: 5895197. doi: 10.1093.
     PubMed     Abstract available
     
     
     
217. KHAN S
     Mast cell tryptase level should be checked in all patients with suspected Kounis syndrome.
     Eur Heart J. 2020;41:3018.
     PubMed    
     
     
     
218. CHATTERJEE NA, Tikkanen JT, Albert CM
     The electrocardiogram and sudden death: capturing electrical physiology and arrhythmic substrate.
     Eur Heart J. 2020;41:2911-2912.
     PubMed    
     
     
     
219. ASATRYAN B, Roten L, Reichlin T
     Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram.
     Eur Heart J. 2020;41:2911-2912.
     PubMed    
     
     
     July 2020
220. WEINGARTNER O, Patel SB, Lutjohann D
     It's time to personalize and optimize lipid-lowering therapy.
     Eur Heart J. 2020;41:2629-2631.
     PubMed    
     
     
     
221. HOWARD JP, Arnold AD, Ahmad Y
     Bias, heterogeneity, and uncertainty in meta-analysis.
     Eur Heart J. 2020;41:2712.
     PubMed    
     
     
     
222. LI Y, Yan L, Shui S, Han X, et al
     Choriocarcinoma metastasis in the left atrium.
     Eur Heart J. 2020;41:2628.
     PubMed    
     
     
     
223. TAN HL, van Dongen LH, Zimmerman DS
     Sudden cardiac death in young patients with diabetes: a call to study additional causes beyond ischaemic heart disease.
     Eur Heart J. 2020;41:2707-2709.
     PubMed    
     
     
     
224. TU S, Westra J, Adjedj J, Wijns W, et al
     Physiological assessment of non-culprit stenoses during acute coronary syndromes.
     Eur Heart J. 2020;41:2598.
     PubMed    
     
     
     
225. WACKER J, Malaspinas I, Aggoun Y, Bordessoule A, et al
     Coronary artery dilatation in a child with hyperinflammatory syndrome with SARS-CoV-2-positive serology.
     Eur Heart J. 2020;41:3103.
     PubMed    
     
     
     June 2020
226. JAYARAJ R, Kumaraswamy C, Shaw P
     Clinical and conceptual approaches to interpreting the findings of systematic review and meta-analysis of mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease.
     Eur Heart J. 2020 Jun 26. pii: 5863013. doi: 10.1093.
     PubMed    
     
     
     
227. STIEKEMA LCA, Hovingh GK, Stroes ESG
     The therapeutic age paradox coming to an end.
     Eur Heart J. 2020;41:2259-2261.
     PubMed    
     
     
     
228. PAVASINI R, D'Ascenzo F, Campo G
     Moving forward from statistical to clinical considerations regarding complete revascularization.
     Eur Heart J. 2020;41:2225.
     PubMed    
     
     
     
229. JOBS A, Schwarzer G, Thiele H
     Conclusions of complete revascularization meta-analysis are challenged by state-of-the-art methods.
     Eur Heart J. 2020;41:2223-2224.
     PubMed    
     
     
     
230. THYGESEN K, Jaffe AS
     Our nearly complete diagnostic trip of thousands of steps begets a new trip therapeutically.
     Eur Heart J. 2020;41:2217-2219.
     PubMed    
     
     
     
231. KONDAPALLI L, Moslehi J, Bonaca MP
     Inflammation begets inflammation: cancer and acute MI.
     Eur Heart J. 2020;41:2194-2196.
     PubMed    
     
     
     
232. DUSI V, De Ferrari GM, Schwartz PJ
     There are 100 ways by which the sympathetic nervous system can trigger life-threatening arrhythmias.
     Eur Heart J. 2020;41:2180-2182.
     PubMed    
     
     
     
233. OLSHANSKY B
     The electrocardiogram: are we at the dawn of a new era?
     Eur Heart J. 2020;41:2000-2002.
     PubMed    
     
     
     May 2020
234. BJORNSTAD JL, Bendz B
     Periprocedural myocardial injury in the EXCEL trial.
     Eur Heart J. 2020;41:1703.
     PubMed    
     
     
     
235. HESS CN, Hiatt WR
     Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back.
     Eur Heart J. 2020;41:1650-1652.
     PubMed    
     
     
     April 2020
236. LUSCHER TF
     Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure.
     Eur Heart J. 2020;41:1311-1314.
     PubMed    
     
     
     March 2020
237. MESSERLI FH, Bangalore S, Messerli AW, Raber L, et al
     The muddy waters of the J-curve and coronary revascularization.
     Eur Heart J. 2020 Mar 2. pii: 5771269. doi: 10.1093.
     PubMed    
     
     
     
238. KIM WC, Sumaya W, Elkhateeb OE
     Fibroelastoma presenting with recurrent myocardial infarction and diagnosed with intracoronary imaging: a novel intracoronary image of fibroelastoma.
     Eur Heart J. 2020 Mar 2. pii: 6157022. doi: 10.1093.
     PubMed    
     
     
     
239. AHMAD Y, Howard JP, Arnold AD, Cook CM, et al
     Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials.
     Eur Heart J. 2020 Mar 2. pii: 5771278. doi: 10.1093.
     PubMed     Abstract available
     
     
     
240. KLEBER ME, Delgado GE, Marz W
     LDL receptor traffic: in the fast lane.
     Eur Heart J. 2020;41:1054-1056.
     PubMed    
     
     
     February 2020
241. LABRECQUE JA, Kaufman JS, Huang JY
     Genetic instruments with too many strings: acknowledging pleiotropy and population structure in Mendelian randomization studies.
     Eur Heart J. 2020;41:892-893.
     PubMed    
     
     
     
242. SINNAEVE P, Van de Werf F
     Primary PCI and the indistinct 120 min time limit.
     Eur Heart J. 2020;41:867-869.
     PubMed    
     
     
     
243. GIANNOPOULOS AA, Gaemperli O
     The power of myocardial blood flow reserve in personalizing management of patients with stable coronary artery disease. Is it time to move on from percentage of ischaemia?
     Eur Heart J. 2020;41:769-771.
     PubMed    
     
     
     January 2020
244. LUSCHER TF
     Chronic coronary syndromes: expanding the spectrum and natural history of ischaemic heart disease.
     Eur Heart J. 2020;41:333-336.
     PubMed    
     
     
     
245. IANNACCONE M, Brilakis ES, Boccuzzi GG
     An App for complex PCI solutions.
     Eur Heart J. 2020;41:342-344.
     PubMed    
     
     
     
246. AL'AREF SJ, Maliakal G, Singh G, van Rosendael AR, et al
     Machine learning of clinical variables and coronary artery calcium scoring for the prediction of obstructive coronary artery disease on coronary computed tomography angiography: analysis from the CONFIRM registry.
     Eur Heart J. 2020;41:359-367.
     PubMed     Abstract available
     
     
     
247. KNUUTI J, Wijns W, Saraste A, Capodanno D, et al
     2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
     Eur Heart J. 2020;41:407-477.
     PubMed    
     
     
     
248. SORBETS E, Fox KM, Elbez Y, Danchin N, et al
     Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.
     Eur Heart J. 2020;41:347-356.
     PubMed     Abstract available
     
     
     
249. PRATI F, Romagnoli E, Gatto L, La Manna A, et al
     Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study.
     Eur Heart J. 2020;41:383-391.
     PubMed     Abstract available
     
     
     
250. HILVO M, Meikle PJ, Pedersen ER, Tell GS, et al
     Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.
     Eur Heart J. 2020;41:371-380.
     PubMed     Abstract available
     
     
     
251. ALI ZA, McEntegart M, Hill JM, Spratt JC, et al
     Intravascular lithotripsy for treatment of stent underexpansion secondary to severe coronary calcification.
     Eur Heart J. 2020;41:485-486.
     PubMed    
     
     
     
252. LEE HS, Chang M, Piccinelli M, Koo BK, et al
     Complete regression of coronary atherosclerosis.
     Eur Heart J. 2020;41:332.
     PubMed    
     
     
     
253. BAUMBACH A, Bourantas CV, Serruys PW, Wijns W, et al
     The year in cardiology: coronary interventions.
     Eur Heart J. 2020 Jan 6. pii: 5694318. doi: 10.1093.
     PubMed    
     
     
     
254. SCHNORBUS B, Daiber A, Jurk K, Warnke S, et al
     Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.
     Eur Heart J. 2020 Jan 3. pii: 5695774. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2019
255. KOGAME N, Serruys PW, Onuma Y
     Cracking (the code of) coronary artery calcification to win the last battle of percutaneous coronary intervention: still in the middle of a rocky road.
     Eur Heart J. 2019 Dec 23. pii: 5686015. doi: 10.1093.
     PubMed    
     
     
     
256. MALMBORG M, Schmiegelow MDS, Norgaard CH, Munch A, et al
     Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
     Eur Heart J. 2019 Dec 20. pii: 5682397. doi: 10.1093.
     PubMed     Abstract available
     
     
     
257. LOPEZ-JIMENEZ F, Gersh BJ
     Secondary prevention after coronary artery bypass grafting saves lives: a golden opportunity often wasted.
     Eur Heart J. 2019 Dec 4. pii: 5651910. doi: 10.1093.
     PubMed    
     
     
     November 2019
258. EBERHARD M, Hermann M, Stahli BE, Manka R, et al
     Amphetamine-induced coronary artery dissection and massive aortic valve thrombus.
     Eur Heart J. 2019 Nov 25. pii: 5640488. doi: 10.1093.
     PubMed    
     
     
     
259. LUSCHER TF
     Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes.
     Eur Heart J. 2019;40:3579-3582.
     PubMed    
     
     
     
260. SINNAEVE PR, Schwartz GG, Wojdyla DM, Alings M, et al
     Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
     Eur Heart J. 2019 Nov 16. pii: 5626150. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2019
261. GARGIULO G, Goette A, Tijssen J, Eckardt L, et al
     Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based rand
     Eur Heart J. 2019 Oct 25. pii: 5607287. doi: 10.1093.
     PubMed     Abstract available
     
     
     
262. BJORKLUND E, Nielsen SJ, Hansson EC, Karlsson M, et al
     Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry.
     Eur Heart J. 2019 Oct 22. pii: 5602556. doi: 10.1093.
     PubMed     Abstract available
     
     
     
263. IBANEZ B
     And fibrinolysis became pharmacoinvasive.
     Eur Heart J. 2019 Oct 12. pii: 5586502. doi: 10.1093.
     PubMed    
     
     
     August 2019
264. TAYAL B, Fruelund P, Sogaard P, Riahi S, et al
     Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study.
     Eur Heart J. 2019 Aug 26. pii: 5554632. doi: 10.1093.
     PubMed     Abstract available
     
     
     
265. LUSCHER TF
     Refining percutaneous coronary intervention: intracoronary imaging, haemodynamics, P2Y12 antagonists, and public outcomes reporting.
     Eur Heart J. 2019;40:2549-2552.
     PubMed    
     
     
     
266. SERRUYS PW, Takahashi K, Chichareon P, Kogame N, et al
     Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
     Eur Heart J. 2019;40:2595-2604.
     PubMed     Abstract available
     
     
     June 2019
267. MEHRA MR, Vaduganathan M, Fu M, Ferreira JP, et al
     A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
     Eur Heart J. 2019 Jun 25. pii: 5522950. doi: 10.1093.
     PubMed     Abstract available
     
     
     
268. CONEN D, Alonso-Coello P, Douketis J, Chan MTV, et al
     Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery.
     Eur Heart J. 2019 Jun 25. pii: 5523034. doi: 10.1093.
     PubMed     Abstract available
     
     
     
269. PIAZZA G, Hurwitz S, Galvin CE, Harrigan L, et al
     Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT).
     Eur Heart J. 2019 Jun 22. pii: 5521151. doi: 10.1093.
     PubMed     Abstract available
     
     
     
270. GENTILLE LORENTE DI
     Coconut atrium: a rare entity to cause pulmonary hypertension.
     Eur Heart J. 2019 Jun 4. pii: 5510776. doi: 10.1093.
     PubMed    
     
     
     May 2019
271. URBAN P, Mehran R, Colleran R, Angiolillo DJ, et al
     Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.
     Eur Heart J. 2019 May 22. pii: 5492739. doi: 10.1093.
     PubMed     Abstract available
     
     
     
272. DEVEREAUX PJ, Szczeklik W
     Myocardial injury after non-cardiac surgery: diagnosis and management.
     Eur Heart J. 2019 May 16. pii: 5490290. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2019
273. JONES DA, Rathod KS, Koganti S, Lim P, et al
     The association between the public reporting of individual operator outcomes with patient profiles, procedural management, and mortality after percutaneous coronary intervention: an observational study from the Pan-London PCI (BCIS) Registry using an
     Eur Heart J. 2019 Apr 10. pii: 5443278. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2019
274. GRABHER F, Hamm W, Massberg S, Orban M, et al
     Uncommon cause of progressive dyspnoea 12 years after coronary artery bypass surgery.
     Eur Heart J. 2019 Mar 12. pii: 5377349. doi: 10.1093.
     PubMed    
     
     
     January 2019
275. KHAN AA, Lip GYH
     Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?
     Eur Heart J. 2019 Jan 21. pii: 5298544. doi: 10.1093.
     PubMed    
     
     
     November 2018
276. POTTS JE, Iliescu CA, Lopez Mattei JC, Martinez SC, et al
     Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States.
     Eur Heart J. 2018 Nov 30. pii: 5221009. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: